GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Neurocrine Biosciences Inc (BSP:N1BI34) » Definitions » Common Stock

Neurocrine Biosciences (BSP:N1BI34) Common Stock : R$1 Mil (As of Sep. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Neurocrine Biosciences Common Stock?

Neurocrine Biosciences's quarterly common stock increased from Mar. 2024 (R$0 Mil) to Jun. 2024 (R$1 Mil) and increased from Jun. 2024 (R$1 Mil) to Sep. 2024 (R$1 Mil).

Neurocrine Biosciences's annual common stock declined from Dec. 2021 (R$1 Mil) to Dec. 2022 (R$1 Mil) and declined from Dec. 2022 (R$1 Mil) to Dec. 2023 (R$0 Mil).


Neurocrine Biosciences Common Stock Historical Data

The historical data trend for Neurocrine Biosciences's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neurocrine Biosciences Common Stock Chart

Neurocrine Biosciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Common Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.41 0.51 0.57 0.53 0.49

Neurocrine Biosciences Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.49 0.49 0.50 0.54 0.55

Neurocrine Biosciences Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.


Neurocrine Biosciences Business Description

Traded in Other Exchanges
Address
12780 El Camino Real, San Diego, CA, USA, 92130
Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.

Neurocrine Biosciences Headlines

No Headlines